EXEL News and Press, Exelixis Inc. From 02/10/26

2026-02-10 18:33:35 ET Image source: The Motley Fool. Tuesday, February 10, 2026 at 5:00 p.m. ET Need a quote from a Motley Fool analyst? Email pr@fool.com Continue reading

2026-02-10 16:10:24 ET More on Exelixis Exelixis: Stock Likely To Go Higher On A Possible Key FDA Approval Exelixis: High-Growth Oncology Name Trading At A Discount Exelixis, Inc. (EXEL) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow Ex...

– Total Revenues of $599 million for the Fourth Quarter of 2025, $2.320 billion for the Fiscal Year 2025 – – Cabozantinib Franchise Achieved $2.123 billion in U.S. Net Product Revenues for the Fiscal Year 2025, including $547 million for the Fourth Quart...

Klaviyo Inc. Series A (KVYO) is expected to report $0.04 for Q4 2025 Diodes Incorporated (DIOD) is expected to report $0.26 for Q4 2025 CRISPR Therapeutics AG (CRSP) is expected to report $-1.15 for Q4 2025 Brighthouse Financial Inc. (BHF) is expected to report $5.19 for Q4 2025 B...

– The FDA assigned a Prescription Drug User Fee Act target action date of December 3, 2026 – – Application is based on results from the phase 3 STELLAR-303 pivotal trial, in which zanzalintinib in combination with atezolizumab improved median overall survi...

2026-01-31 19:13:00 ET In the volatile biotech industry, companies can see their shares soar over relatively short periods on strong clinical progress for exciting pipeline candidates. That's precisely what could happen to Exelixis (NASDAQ: EXEL) and Summit Therapeutics (N...

2026-01-28 22:06:01 ET ... Read the full article on Seeking Alpha For further details see: Exelixis: Stock Likely To Go Higher On A Possible Key FDA Approval

– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (Nasdaq: EXEL) announced today that its fourth quarter and fiscal year 2025 financial results will be released on Tuesday, February 10, 2026 after the markets close. At 5:00 p.m. ...

2026-01-22 07:22:08 ET Investment Thesis Read the full article on Seeking Alpha For further details see: Exelixis: High-Growth Oncology Name Trading At A Discount

2026-01-16 13:49:19 ET More on healthcare stocks XLV Vs. BME: Total Return Or Income, Which Healthcare Strategy Wins? Cardinal Health, Inc. (CAH) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow Cardinal Health, Inc. (CAH) Presents at 44th Annual...